Technology

Israel Launches NIS 70 Million Bio-AI Consortium

Published

Israel Launches NIS 70 Million Bio-AI Consortium

The Israel Innovation Authority and industry partners will invest about NIS 70 million in a new national consortium to build artificial-intelligence infrastructure for biology, drug discovery and personalized medicine. The Israel BioToken Factory Initiative brings together NVIDIA, Teva, Sheba Medical Center, CytoReason, TerraCyte, MeMed and researchers from Weizmann, the Technion and Ben-Gurion University. Its shared Bio Tokens layer and Factory Model platform are designed to integrate molecular, cellular, dynamic and clinical data. Initial applications include oncology-treatment response, immune activity, drug hypersensitivity, sepsis decisions, transplant rejection, autoimmune disease and drug discovery.

Sources

Primary sources:1Secondary sources:234

Related stories

  1. Israeli AIR Chooses Florida Hub for U.S. eVTOL Production
  2. Teva Shares Jump 9% as Innovative Drug Sales Top $1 Billion
  3. Stark Power Raises NIS 145 Million, Migdal Becomes Substantial Shareholder
  4. Syngenta to Market Israeli Groundwork BioAg Crop Technology
  5. Redis Cuts Roughly a Quarter of Its Israel Workforce

Something went wrong

We couldn't complete that action. Check your connection and try again.